Yes, please.
I want to talk about your second question about commercialization. Commercialization is a little tricky in Canada compared to the United States, because in Canada you have the New Substances Assessment and Control Bureau, which is there to accept or refuse this new product. For example, if I come with a new product and I say it's not dangerous at all, the new substances office has to prove this is dangerous. If they don't have any proof, they have no choice but to accept it. What we have here—and we said this a couple of times—is we don't have all the pieces of the puzzle to correctly characterize nanotechnology and nanoparticles.
In the U.S., the EPA has to look at this commercial product. If they don't have enough information, they will return the folder to the company and say they need more experimental data to be able to assess this new commercial product. We don't have this procedure here. It's regulated by law, so I think something needs to be done to be sure we will protect Canadians.